Cardiovascular Program: Preclinical Programs
Our preclinical programs focus on the development of second generation 
inhibitors in addition to A–001 and A–002. Our most advanced molecule, A–003,
is a novel compound that belongs to a distinct class of inhibitors‚ and shows increased potency against enzymes. A-003 is being evaluated in preclinical
efficacy and safety studies for the development of a second generation inhibitor for the treatment of cardiovascular diseases.
In addition to the cardiovascular second generation program, we are focusing on developing novel therapies that target inflammatory diseases of the skin. The
therapeutic effect of inhibition of in dermatitis, eczema and psoriasis, is also the focus of our preclinical programs.
Y. H. Pan‚ B. Z. Yu‚ A. G. Singer‚ F. Ghomashchi‚ G. Lambeau‚ M. H. Gelb‚ M. K. Jain‚ and B. J. Bahnson* (2002) Crystal Structure of Human Group–X Secreted Phospholipase A2; Electrostatically Neutral Interfacial Binding Surface Targets Zwitterionic Membranes‚ Journal of Biological Chemistry‚ 277‚ 29086–29093.